NovaBridge Biosciences: Form 20-F for the period ended Dec 31, 2024
Filed with the SEC on Apr 3, 2025 and accepted by EDGAR at Apr 3, 2025, 16:01 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2024-01-01 to 2024-12-31 | $21.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −$51.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2024-01-01 to 2024-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$22.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 186,728,372 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$52.7m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | $48.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | $68.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $176.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $212.7m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $8.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $11.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $201.2m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-12-31 | 187,452,495 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000950170-25-050344. Last ingested by Listed: Oct 28, 2026, 07:01 ET. Listed shows no prices and gives no investment advice.